Back to Search
Start Over
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
- Source :
- Annals of Internal Medicine; 2/16/2021, Vol. 174 Issue 2, p221-228, 8p, 1 Diagram, 2 Charts, 1 Graph
- Publication Year :
- 2021
-
Abstract
- Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and statistical reasoning. The plausibility that vaccine protection against symptomatic COVID-19 could be accompanied by a shift toward more SARS-CoV-2 infections that are asymptomatic is highlighted, as well as the potential implications of such a shift. [ABSTRACT FROM AUTHOR]
- Subjects :
- COVID-19
COVID-19 vaccines
VACCINE trials
VACCINE effectiveness
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 00034819
- Volume :
- 174
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Annals of Internal Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 148754999
- Full Text :
- https://doi.org/10.7326/M20-6169